Clinical Trial Update: A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation [Phase 2]

View source ↗

Summary

Phase 2 study of vemurafenib in metastatic or unresectable papillary thyroid carcinoma with BRAF V600 mutation; results were posted after study completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillary Thyroid Carcinoma

Drugs mentioned

• Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2016-09-07